BIO 300 and radiation for lung cancer with lung scarring
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have early-stage (stage I or II) non-small cell lung cancer.
- You have interstitial lung disease (lung scarring) diagnosed by a pulmonologist, by imaging, or due to a connective tissue disease.
- You are able to care for yourself (ECOG performance status 0-3).
- You have not had radiation to the chest before.
- You have not had a lung removed (pneumonectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests whether focusing radiation only on the main tumor (not the surrounding area) is safe and effective for people with stage 3 lung cancer that cannot be removed with surgery. It aims to reduce side effects while keeping the treatment working.
This trial tests a new combination of radiation therapy, an immunotherapy drug (tislelizumab), and chemotherapy to shrink bulky stage III lung cancer before possible surgery. The goal is to see if this approach is safe and effective.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Hear when a new NSCLC, Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.